SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-17-191279
Filing Date
2017-06-01
Accepted
2017-06-01 16:47:03
Documents
6
Period of Report
2017-01-09
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM 8-K d403366d8ka.htm 8-K/A 23845
2 CONSENT OF CHERRY BEKAERT LLP d403366dex231.htm EX-23.1 1701
3 CONSENT OF PRICEWATERHOUSECOOPERS LLP d403366dex232.htm EX-23.2 1687
4 STATEMENT OF NET ASSETS ACQUIRED (AUDITED) OF THE BELBUCA PRODUCT LINE d403366dex991.htm EX-99.1 24093
5 STATEMENT OF REVENUES AND DIRECT EXPENSES (AUDITED) OF THE BELBUCA PRODUCT LINE d403366dex992.htm EX-99.2 42269
6 UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS d403366dex993.htm EX-99.3 78983
  Complete submission text file 0001193125-17-191279.txt   173769
Mailing Address 4131 PARKLAKE AVENUE SUITE 225 RALEIGH NC 27612
Business Address 4131 PARKLAKE AVENUE SUITE 225 RALEIGH NC 27612 919 582 9050
BIODELIVERY SCIENCES INTERNATIONAL INC (Filer) CIK: 0001103021 (see all company filings)

IRS No.: 352089858 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-31361 | Film No.: 17885327
SIC: 2834 Pharmaceutical Preparations